<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2026"
  xmlns:ffd="http://xbrl.sec.gov/ffd/2026"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef
      xlink:href="https://xbrl.sec.gov/ffd/2026/ffd-2026.xsd"
      xlink:type="simple"/>
    <context id="rc">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
        </entity>
        <period>
            <startDate>2026-11-18</startDate>
            <endDate>2026-11-18</endDate>
        </period>
    </context>
    <context id="offrl_1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000872589</identifier>
            <segment>
                <xbrldi:typedMember dimension="ffd:OfferingAxis">
                    <dei:lineNo>1</dei:lineNo>
                </xbrldi:typedMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-11-18</startDate>
            <endDate>2026-11-18</endDate>
        </period>
    </context>
    <unit id="USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="pure">
        <measure>pure</measure>
    </unit>
    <unit id="Shares">
        <measure>shares</measure>
    </unit>
    <ffd:FormTp contextRef="rc" id="ixv-168">S-8</ffd:FormTp>
    <ffd:SubmissnTp contextRef="rc" id="ixv-169">S-8</ffd:SubmissnTp>
    <ffd:FeeExhibitTp contextRef="rc" id="ixv-170">EX-FILING FEES</ffd:FeeExhibitTp>
    <dei:EntityCentralIndexKey contextRef="rc" id="ixv-171">0000872589</dei:EntityCentralIndexKey>
    <dei:EntityRegistrantName contextRef="rc" id="ixv-172">REGENERON PHARMACEUTICALS, INC.</dei:EntityRegistrantName>
    <ffd:OfferingTableNa contextRef="rc" id="hiddenrcOfferingTableNa" xsi:nil="true"/>
    <ffd:OffsetTableNa contextRef="rc" id="hiddenrcOffsetTableNa">N/A</ffd:OffsetTableNa>
    <ffd:PrevslyPdFlg contextRef="offrl_1" id="ixv-175">false</ffd:PrevslyPdFlg>
    <ffd:FormTp contextRef="rc" id="ixv-200">S-8</ffd:FormTp>
    <dei:EntityRegistrantName contextRef="rc" id="ixv-201">REGENERON PHARMACEUTICALS, INC.</dei:EntityRegistrantName>
    <ffd:OfferingSctyTp contextRef="offrl_1" id="ixv-202">Equity</ffd:OfferingSctyTp>
    <ffd:OfferingSctyTitl contextRef="offrl_1" id="ixv-203">Common stock, par value $0.001 per share, issuable pursuant to the Second Amended and Restated 2014 Plan</ffd:OfferingSctyTitl>
    <ffd:FeesOthrRuleFlg contextRef="offrl_1" id="ixv-204">true</ffd:FeesOthrRuleFlg>
    <ffd:AmtSctiesRegd
      contextRef="offrl_1"
      decimals="0"
      id="ixv-205"
      unitRef="Shares">12000000</ffd:AmtSctiesRegd>
    <ffd:MaxOfferingPricPerScty
      contextRef="offrl_1"
      decimals="2"
      id="ixv-206"
      unitRef="USD">951.97</ffd:MaxOfferingPricPerScty>
    <ffd:MaxAggtOfferingPric
      contextRef="offrl_1"
      decimals="2"
      id="ixv-207"
      unitRef="USD">11423640000.00</ffd:MaxAggtOfferingPric>
    <ffd:FeeRate
      contextRef="offrl_1"
      decimals="6"
      id="ixv-208"
      unitRef="pure">0.000087</ffd:FeeRate>
    <ffd:FeeAmt
      contextRef="offrl_1"
      decimals="2"
      id="ixv-209"
      unitRef="USD">993856.68</ffd:FeeAmt>
    <ffd:TtlOfferingAmt contextRef="rc" decimals="2" id="ixv-210" unitRef="USD">11423640000.00</ffd:TtlOfferingAmt>
    <ffd:TtlFeeAmt contextRef="rc" decimals="2" id="ixv-211" unitRef="USD">993856.68</ffd:TtlFeeAmt>
    <ffd:TtlOffsetAmt contextRef="rc" decimals="2" id="ixv-212" unitRef="USD">0.00</ffd:TtlOffsetAmt>
    <ffd:NetFeeAmt contextRef="rc" decimals="2" id="ixv-213" unitRef="USD">993856.68</ffd:NetFeeAmt>
    <ffd:OfferingNote contextRef="offrl_1" id="ixv-214">Pursuant to Rule 416(a) under the Securities Act of 1933, as amended (the "Securities Act"), this Registration Statement shall also cover any additional shares of Common Stock that become issuable under the Second Amended and Restated Regeneron Pharmaceuticals, Inc. 2014 Long-Term Incentive Plan (the "Second Amended and Restated 2014 Plan") by reason of any stock dividend, stock split, recapitalization or similar transaction effected without receipt of consideration that increases outstanding Common Stock.

The "Amount Registered" represents an additional 12,000,000 shares of Common Stock reserved for issuance under the Second Amended and Restated 2014 Plan.

The "Proposed Maximum Offering Price Per Unit" and "Maximum Aggregate Offering Price" are estimated solely for the purpose of calculating the registration fee pursuant to Rules 457(c) and 457(h) under the Securities Act, based on the average of the high and low prices of the Registrant's Common Stock as reported on the Nasdaq Global Select Market on November 13, 2026.
</ffd:OfferingNote>
</xbrl>
